Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04969029CT.gov Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tirelizumab (this asset) | Tianjin Medical University Cancer Institute and Hospital | P2 | CCC · 48 |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Fluorouracilum | Akeso | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Pertuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | BB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Trastuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Palbociclib | Lebanese University | P2 | BB |
+42 more in the Colon Carcinoma cohort
Other indications for Tirelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | BB · 65 |
| Hepatocellular Carcinoma | — | P4 | B · 62 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tirelizumab in Colon Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tirelizumab-colon-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →